Welwaze Medical

Executive Summary

Welwaze Medical is a Miami-based digital health and diagnostics company founded in 2015 that focuses on breast health. The company has developed Celbrea®, a thermal activity indicator, along with a mobile app for self-examination guidance and an integrated AI platform. These solutions aim to make breast health data more accessible to patients and healthcare professionals, potentially improving early detection and monitoring. Welwaze is well-positioned in the growing digital health market, leveraging AI and mobile technology to address a critical need in women's health. Despite limited public information on funding or commercial traction, Welwaze's focus on non-invasive, accessible diagnostics aligns with healthcare trends toward remote monitoring and early intervention. The company's private status and absence of disclosed revenue or partnerships suggest it may still be in early commercialization or seeking regulatory approvals. However, its technology could fill a gap in breast health screening, especially in underserved areas. If the Celbrea device gains regulatory clearance and clinical adoption, Welwaze could become a notable player in the digital diagnostics space.

Upcoming Catalysts (preview)

• Q2 2026FDA 510(k) clearance for Celbrea thermal activity indicator40% success
• Q4 2026Strategic partnership with a major hospital system or insurer50% success
• Q1 2027Launch of AI-powered predictive analytics feature for breast health monitoring60% success